Antibody Drug Conjugates: Link Your Antibody To Its Fullest Potential

Samsung Biologics, a leading Contract Development and Manufacturing Organization (CDMO), is expanding into the production of Antibody-Drug Conjugates (ADCs). Leveraging its existing expertise and state-of-the-art facilities, the company offers a comprehensive suite of ADC services, including development, manufacturing, and supply chain management. Their integrated approach combines antibody production, conjugation development, and manufacturing under one roof, minimizing risk and expediting time to market.

Key benefits include:

• Dedicated ADC facility with flexible batch size capabilities.
• Single-site operation for streamlined efficiency and risk management.
• Comprehensive services encompassing the entire ADC development and manufacturing process.
• Cutting-edge technology and expertise to ensure high-quality product delivery.

Download the brochure to learn more about how Samsung Biologics can help you bring your ADC therapy to market faster.